Ask AI
Targeted Agents in Relapsed ES SCLC

CE / CME

Translating Evidence to Action in Relapsed ES-SCLC: Integrating New Targeted Agents Into Clinical Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 25, 2025

Expiration: May 24, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Daniel Morgensztern, MD, provides an overview of key clinical trials evaluating new targeted agents used to manage patients with relapsed ES-SCLC. This module is part of a larger program on SCLC and additional modules can be found here.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 56-year-old patient with a history of chronic obstructive pulmonary disease was diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) 6 months ago and received first-line etoposide, carboplatin, and durvalumab for 4 cycles, followed by 3 months of durvalumab maintenance. A PET scan after the third cycle of maintenance showed progressive disease (PD) with new lymph node, chest wall, and liver metastases. MRI reveals 2 subcentimeter, asymptomatic brain metastases. The patient has an Eastern Cooperative Oncology Group performance status of 0, adequate labs, and no symptoms.

Which of the following systemic treatment options would you select for this platinum-refractory patient?

In the phase Ib DAREON-9 trial evaluating obrixtamig combined with topotecan for relapsed SCLC, which of the following outcomes was observed?

How many people with SCLC do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: